You are here: Industry Insights > NK cells

News List

Celularity Doses First Patient in Trial Evaluating CYNK-001 in COVID-19 Patients americanpharmaceuticalreview
September 24, 2020
Celularity announced the first patient was dosed in a Phase I/II study of human placental hematopoietic stem cell derived NK cells (CYNK-001) for the treatment of adults with COVID-19 as part of a national clinical trial.
Kiadis to collaborate with Abigail Wexner Research Institute for clinical trials of COVID-19 therapy expresspharma
September 15, 2020
The US FDA approved AWRI’s investigational new drug application (IND) for a study in an adult population with off-the-shelf natural killer (NK) cells.
Therapeutic Solutions to Use Clinical Stage NK Activating Cancer Immunotherapy for COVID-19 americanpharmaceuticalreview
July 02, 2020
Therapeutics Solutions has announced plans to utilize its clinical-stage cancer immunotherapy StemVacs™ for treatment of COVID-19 patients.
Gilead, oNKo-innate to develop NK cells-focused cancer immunotherapies pharmaceutical-business-review
April 26, 2020
Gilead Sciences and its subsidiary Kite have joined forces with oNKo-innate to discover and develop cancer immunotherapies focused on natural killer (NK) cells.